Pazopanib has been shown to be clinically effective in metastatic urothelial cancer, according to the final results of a study conducted by Andrea Necchi and colleagues. In the phase II trial, 41 patients with refractory disease who had been previously treated with chemotherapy received 800 mg once-daily pazopanib. At follow-up, 17% had a partial response to therapy and 59% patients had stable disease, which translates into 76% of patients benefiting from the drug. Median progression-free survival and overall survival were 2.6 months and 4.7 months, respectively. More importantly, interleukin-8 was identified as clear indicator of tumour progression and shorter overall survival after just 4 weeks of treatment.
ORIGINAL RESEARCH PAPER
Necchi, A. et al. Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer [Abstract LB-433]. Presented at the AACR annual meeting (Chicago, IL, 2012)
Rights and permissions
About this article
Cite this article
Antiangiogenic therapy works in metastatic urothelial cancer. Nat Rev Clin Oncol 9, 307 (2012). https://doi.org/10.1038/nrclinonc.2012.80
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.80